Allergan Comments on FDA Requested Class Labeling for Botulinum Toxin Treatments in Connection with Approval of Dysport
Proper Education on Toxin Non-Interchangeability Critical to Mitigate Patient Risks IRVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2009 - Allergan, Inc. (NYSE: AGN) commented today on Ipsen's and Medicis's joint announcement that the U.S. Food and Drug...